Injectable peptide drugs targeting the glucagon-like peptide 1 (GLP-1) receptor have had massive impact on approaches to treating diabetes and obesity, bringing huge revenue boosts to makers Novo Nordisk and Eli Lilly. Meanwhile, evidence is…
The challenge of developing oral alternatives to Ozempic, Wegovy and Mounjaro
